Status:
UNKNOWN
Analysis of the Pathophysiology and Pathology of Coronavirus Disease 2019 (COVID-19), Including Chronic Morbidity
Lead Sponsor:
Charite University, Berlin, Germany
Collaborating Sponsors:
Network University Medicine NUM
Berlin Institute of Health
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
NAPKON-HAP is the deep phenotyping platform of the National Pandemic Cohort Network (NAPKON) in Germany. NAPKON is a data and biospecimen collection of patients with COVID-19 and is part of the Univer...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Willingness to participate in the study (consent to participate by patient or appropriate legal representative) or inclusion via deferred consent
- Hospitalization at time of enrollment
- Positive evidence for SARS-CoV-2 infection with PCR (polymerase chain reaction) or initial positive rapid diagnostic test in conjunction with typical clinical symptoms, confirmed by a later positive PCR test.
Exclusion
- Refusal to participate by patient, or appropriate legal representative
- Any condition that prohibits supplemental blood-sampling beyond routine blood drawing
Key Trial Info
Start Date :
November 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2025
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT04747366
Start Date
November 6 2020
End Date
November 30 2025
Last Update
February 10 2021
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Freiburg Department of Internal Medicine II Department of Infectiology
Freiburg im Breisgau, Baden-Wurttemberg, Germany, 79106
2
University Hospital Heidelberg Clinic for Gastroenterology, Infections, Poisoning
Heidelberg, Baden-Wurttemberg, Germany, 69120
3
Clinic of the University of Munich Medical Clinic and Polyclinic III
Munich, Bavaria, Germany, 81377
4
University Hospital Frankfurt Medical Clinic II Department of infectiology
Frankfurt am Main, Hesse, Germany, 60590